• 4D Molecular Therapeutics President, CEO, director David Kirn sold 1,922 common shares on June 1, 2026.
• Sale priced at USD 10.02 per share, leaving him with 1,057,231 shares held directly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-253740), on June 02, 2026, and is solely responsible for the information contained therein.